Acarix AB (publ) (7AC.F)
| Previous Close | 0.0200 |
| Open | 0.0198 |
| Bid | 0.0261 x 0 |
| Ask | 0.0359 x 0 |
| Day's Range | 0.0198 - 0.0198 |
| 52 Week Range | 0.0152 - 0.0461 |
| Volume | |
| Avg. Volume | 418 |
| Market Cap | 29.493M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Feb 13, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireAcarix Expands U.S. Reimbursement Coverage for CADScor System for use in Emergency and Outpatient Settings
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has decided that the CPT code 0716T - the CADScor® System - shall be assigned to APC 5733 including status indicator assignment to "S" (separately payable) for calendar year 2025. The CMS ruling means standalone fixed reimbursement is now possible for the CADScor System in outpatient settings.
- PR Newswire
Acarix AB (publ) publishes Interim Report, April - June 2024
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 2024. The company achieved record-breaking patch sales and record-breaking gross profit, driven by the success of its new sales model coupled with key strategic initiatives involving commercial expansion and clinical activities. These results highlight the company's growing market presence and commitment to innovation in the cardiac diagnostics space.
